Bibliography
- Lassen MR, Davidson BL, Gallus A, The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Throb Haemost 2007;5:2368-75
- Borris CL. Rivaroxaban, a new, oral direct factor Xa inhibitor for thromboprohylaxis after major joint arthroplasty. Expert Opin Pharmacother 2009;10:1083-88
- Kubitza D, Becka M, Wensing G, Safety, pharmacodynamics and pharmacokinetics of single doses of BAY 59 – 7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-21
- Kubitza D, Becka M, Wensing G, Safety, pharmacodynamics and pharmacokinetics of single doses of BAY 59 – 7939, an oral, direct factor Xa inhibitor after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80
- Graff J, von Hentig N, Misselwitz F, Effects of the oral, direct factor Xa inhibitor Rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007;47:1398-407
- Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006;15:843-55
- Eriksson BI, Borris LC, Friedman RJ, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75
- Kakkar AK, Brenner B, Dahl OE, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; doi:10.1016/S0140-6736(08)60880-6
- Lassen MR, Ageno W, Borris LC, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86
- Turpie GA, Lassen MR, Davidson BL, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial. Lancet 2009;373:1673-80